Valproic Acid, an Antiepileptic Drug with Histone Deacetylase Inhibitory Activity, Potentiates the Cytotoxic Effect of Apo2L/TRAIL on Cultured Thoracic Cancer Cells through Mitochondria-Dependent Caspase Activation

This publication has 72 references indexed in Scilit:

• Targeting the Epigenome for the Treatment and Prevention of Lung Cancer
  Seminars in Oncology, 2005
• Adjuvant Chemotherapy for Non–Small Cell Lung Cancer: Contribution of the International Adjuvant Lung Trial
  Clinical Cancer Research, 2005
• HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
  British Journal of Cancer, 2005
• Depsipeptide (FR901228) Enhances the Cytotoxic Activity of TRAIL by Redistributing TRAIL Receptor to Membrane Lipid Rafts
  Molecular Therapy, 2005
• Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies
  Cell Death & Differentiation, 2004
• Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation
  Cancer Research, 2004
• Anti‐tumor mechanisms of valproate: A novel role for an old drug
  Medicinal Research Reviews, 2002
• BID-dependent and BID-independent pathways for BAX insertion into mitochondria
  Cell Death & Differentiation, 2000
• Safety and antitumor activity of recombinant soluble Apo2 ligand
  Journal of Clinical Investigation, 1999
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
  Journal of Biological Chemistry, 1996